First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
AnaptysBio announced that its upcoming spin-off, First Tracks Biotherapeutics, secured $145 million through a private placement, including $80 million from the sale of primary shares. The spin-off, expected to complete on April 20, 2026, will launch with approximately $180 million in cash and a two-year cash runway to support clinical development o…